We are international
Donate
TEXT SIZE   


Module 2: First-Line Treament of Multiple Myeloma
08.08.02

Module 2: First-Line Treatment of Multiple Myeloma

Release Date: August 2002
Expiration Date: August 31, 2003

Program Overview

THIS MODULE IS IN THE PROCESS OF BEING UPDATED. First-Line Treatment of Multiple Myeloma includes discussions of steroid therapy, stem cell transplants, advances in the use of thalidomide, and the treatment of myeloma bone disease.

Learning Objectives

After completing Module 2, participants should be able to do the following:

1. Discuss the current treatment options for multiple myeloma and their side effects.
2. Detail the types of transplantation and their indications.
3. Describe the benefits and risks of treatment options.
4. Identify which drugs are now available and which are still in development.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Institute for Continuing Healthcare Education and the International Myeloma Foundation. The Institute for Continuing Healthcare Education is accredited by the ACCME to provide continuing medical education for physicians.

The Institute for Continuing Healthcare Education designates this activity for a maximum of 2.0 hours in category 1 credit toward the AMA Physician s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the activity.

Begin Activity


 related articles